Late-breaking oral presentation of the L301 FIRSTLUNG Study highlights first-of-its-kind evidence that a blood-based test can increase lung cancer screening uptake; five total presentations span ...
PALO ALTO, Calif., May 13, 2026 /PRNewswire/ -- DELFI Diagnostics, Inc., developer of innovative blood-based tests that leverage cell-free DNA (cfDNA) fragmentomics for cancer detection and monitoring ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results